X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Fresenius Kabi Onco. Fact Sheet, Fresenius Kabi Onco. Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Fresenius Kabi Onco. Fact Sheet   (DBPH)

Here is the latest financial fact sheet of Fresenius Kabi Onco.. For more details, see the Fresenius Kabi Onco. quarterly results and Fresenius Kabi Onco. share price and chart. For a sector overview, read our pharmaceuticals sector report.

FRESENIUS KABI ONCO. Price History

Price Rs 132.5
Mkt Cap Rs m 20,958
Vol '000 91.5
P/E X 22.1
P/CF X 19.7
EPS (TTM) Rs 6.0
% ch % 0.3
No. of shares m 158.23
% ch week % 0.4
% ch 1-mth % 1.9
% ch 12-mth % 20.1
52 week H/L Rs 161.4/93.1
(As on Jan 2, 2014 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

FRESENIUS KABI ONCO. Financials

No. of Mths
Year Ending
12
Mar-09
*
12
Mar-10
*
12
Mar-11
12
Mar-12
12
Mar-13
5-Yr Chart
Click to enlarge
FRESENIUS KABI ONCO. EQUITY SHARE DATA
High Rs81163194165176 
Low Rs2935828279 
Sales per share (Unadj.) Rs19.730.226.133.337.7 
Earnings per share (Unadj.) Rs-9.2-2.13.13.25.1 
Diluted earnings per shareRs-9.2-2.13.13.25.1 
Cash flow per share (Unadj.) Rs-7.4-0.14.24.76.7 
Dividends per share (Unadj.) Rs00000 
Adj. dividends per shareRs0.000.000.000.000.00 
Dividend yield (eoy) %00000 
Book value per share (Unadj.) Rs17.815.734.237.542.5 
Adj. book value per shareRs17.815.734.237.542.5 
Shares outstanding (eoy) m158.23158.23158.23158.23158.23 
Bonus/Rights/Conversions  PI---- 
Price / Sales ratio x2.83.35.33.73.4 
Avg P/E ratio x-6.0-47.044.338.425.0 
P/CF ratio (eoy) x-7.4-1,103.233.026.118.9 
Price / Book Value ratio x3.16.34.03.33.0 
Dividend payout %00000 
Avg Mkt Cap Rs m8,70315,66521,83619,54120,135 
No. of employees `0000.80.91.11.11.2 
Total wages/salary Rs m1,008695561610703 
Avg. sales/employee Rs Th3,789.65,088.43,649.64,784.55,176.2 
Avg. wages/employee Rs Th1,222.9738.9496.1553.9610.4 
Avg. net profit/employee Rs Th-1,772.0-354.9435.4462.7699.6 
FRESENIUS KABI ONCO. INCOME DATA
Net Sales Rs m3,1234,7834,1285,2685,963 
Other income Rs m223140592918 
Total revenues Rs m3,3464,9234,1875,2975,981 
Gross profit Rs m-1,2342277376591,430 
Depreciation Rs m282319169240258 
Interest Rs m291322-47177-26 
Profit before tax Rs m-1,585-2756732721,216 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m153027445-68 
Tax Rs m2859208208342 
Profit after tax Rs m-1,460-334492509806 
Gross profit margin %-39.54.717.812.524.0 
Effective tax rate %-1.8-21.430.876.328.1 
Net profit margin %-46.8-7.011.99.713.5 
FRESENIUS KABI ONCO. BALANCE SHEET DATA
Current assets Rs m3,5635,4205,4524,6795,102 
Current liabilities Rs m3,5444,5963,8382,0902,385 
Net working cap to sales %0.617.239.149.245.6 
Current ratio x1.01.21.42.22.1 
Inventory Days Days166187183129150 
Debtors Days Days11798156140113 
Net fixed assets Rs m4,8975,2803,5394,4535,148 
Share capital Rs m158158158158158 
"Free" reserves Rs m2,6422,3092,4695,7506,556 
Net worth Rs m2,8112,4825,4135,9266,732 
Long term debt Rs m2,0163,602952952952 
Total assets Rs m8,53710,78410,5929,21310,388 
Interest coverage x-4.40.1-13.42.5-45.8 
Debt to equity ratio x0.71.50.20.20.1 
Sales to assets ratio x0.40.40.40.60.6 
Return on assets %-13.7-0.14.27.47.5 
Return on equity %-51.9-13.49.18.612.0 
Return on capital %-23.60.810.313.014.6 
Exports to sales %59.174.280.877.274.5 
Imports to sales %16.315.819.318.724.8 
Exports (fob) Rs m1,8463,5513,3354,0694,441 
Imports (cif) Rs m5087547969861,477 
Fx inflow Rs m1,9573,6103,3614,0725,298 
Fx outflow Rs m9089559911,2501,772 
Net fx Rs m1,0492,6542,3702,8223,525 
FRESENIUS KABI ONCO. CASH FLOW
From Operations Rs m -1,867 -724 500 1,743 1,274 
From Investments Rs m 535 -661 -1,157 168 -1,204 
From Financial Activity Rs m 1,409 1,504 492 -1,965 -196 
Net Cashflow Rs m 77 120 -165 -54 -126 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 81.0%
Indian inst/Mut Fund 0.3%
FIIs 9.6%
ADR/GDR 0.0%
Free float 9.1%
Shareholders 42,599
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B-310, Som Datt Chambers - 1, Bhikaji Cama Place, New Delhi -110 066
E-MAIL complianceofficer.india@fresenius-kabi.com WEB www.fresenius-kabi-oncology.com
TELEPHONE (011) 2610 5570 FAX (011) 2619 5965
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT MCS Limited, F-65, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-20
AUDITOR G. Basu & Co.
CHM: Rakesh Bhargava COMP SEC: Nikhil Kulshreshtha YEAR OF INC: 2004 BSE CODE: 532545 FV (Rs): 1 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA  PLETHICO PHARMA  IPCA LABS  UNICHEM LAB  PFIZER  

Compare FRESENIUS KABI ONCO. With:   SUN PHARMA  PLETHICO PHARMA  IPCA LABS  UNICHEM LAB  PFIZER  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Share Markets End the Week on a Dull Note(RoundUp)

Global financial markets ended the week on a dull note. This was on back of the Federal Reserve's release of its May 2-3 policy meeting minutes.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Bitcoin at $10,000?(Vivek Kaul's Diary)

Jun 14, 2017

Whether you're Venezuela or China or in India or the US...and you want to protect your wealth, you need real money. All the government has on offer is funny money.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ADCOCK INGRAM COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS